GSK, Pfizer Dismiss RSV Lawsuit
This is a news story, published by Yahoo Finance, that relates primarily to GlaxoSmithKline news.
GlaxoSmithKline news
For more GlaxoSmithKline news, you can click here:
more GlaxoSmithKline newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
GSK patents. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest vaccine news, respiratory syncytial virus news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
vaccine AbrysvoReuters
•Health
Health
GSK resolves patent lawsuit against Pfizer over RSV vaccines

76% Informative
GlaxoSmithKline and Pfizer have agreed to end a lawsuit that alleged Pfizer 's respiratory syncytial virus ( RSV ) vaccine Abrysvo violated GSK 's patent rights in its competing RSV shot Arexvy.
The respiratory disease typically causes cold-like symptoms, but it is also a leading cause of pneumonia in toddlers and older adults.
GSK , Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration .
VR Score
87
Informative language
94
Neutral language
21
Article tone
formal
Language
English
Language complexity
58
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links
Small business owner?